Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Gansevoort, R.; Arıcı, M.; Benzing, T.; Birn, H.; Capasso, G.; Covic, A.; Devuyst, O.; Drechsler, C.; Eckardt, K.; Emma, F.; Knebelmann, B.; Le Meur, Y.; Massy, Z.; Ong, A.; Ortiz, A.; Schaefer, F.; Torra, R.; Vanholder, R.; Więcek, A.; Zoccali, C.; van Biesen, W.

doi:10.1093/ndt/gfv456

Public

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Shared by NobleBlocks on Jan 29, 2016 • 12:00 AM UTC

Authors:

R. Gansevoort

M. Arıcı

T. Benzing

Abstract

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiat...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!